Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection

By LabMedica International staff writers
Posted on 29 Sep 2026

Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. More...

Early detection remains critical, but cancer biomarkers can produce only faint signals in blood samples, while conventional blood-based tests may require lengthy preparation and have limited sensitivity at very low concentrations. Researchers have now developed a laser-powered approach designed to enable faster detection of a colorectal cancer biomarker.

Researchers at Osaka Metropolitan University developed the approach using a microflow-type Light-induced Acceleration System (LAC-SYS) for rapid and sensitive biomarker detection. The technology is designed to detect glycoprotein CEACAM-5, a biomarker associated with colorectal cancer. The study was published in Nanoscale Horizons on June 29, 2026.

The method uses microscopic beads coated with multiple antibodies, which are introduced into a small flow channel containing blood plasma. When the sample is exposed to laser irradiation, LAC-SYS enhances interactions between the antibody-coated beads and CEACAM-5, causing the beads to assemble and produce a measurable signal.

The researchers tested the system using diluted blood plasma samples. For each experiment, 5 µL of plasma was serially diluted, with 1,000-fold diluted samples used primarily for patients with colorectal cancer. The method detected CEACAM-5 at concentrations of 1–10 picograms per milliliter in diluted plasma, representing a potential sensitivity improvement of one to two orders of magnitude compared with conventional immunoassays such as enzyme-linked immunosorbent assays and immunoprecipitation.

Further analysis showed that CEACAM-5 exists in blood as nanoscale aggregates. These clusters may interact efficiently with the antibody-coated beads, promoting bead assembly and strengthening the resulting detection signal. Based on this mechanism, the researchers said the technology could potentially be adapted to other disease-related biomarkers, including those associated with dementia and infectious diseases.

The next step is to validate the technology in clinical settings and determine how reliably it can distinguish disease-related signals in patient samples. The team also plans to work with industry partners to develop practical, portable diagnostic systems for broader use.

“Ultimately, our goal is to establish a rapid, highly sensitive, and minimally invasive platform for liquid biopsy and other blood-based diagnostic technologies that can support earlier disease detection and intervention,” said Takuya Iida, professor at the Graduate School of Science and Research Institute for LAC-SYS (RILACS) at Osaka Metropolitan University and lead author of this study.

Related Links
Osaka Metropolitan University 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.